Literature DB >> 12882349

Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?

Deepinder Kaur1, Julie K Andersen.   

Abstract

Levels of iron are increased in the brains of Parkinson's disease (PD) patients compared to age-matched controls. This has been postulated to contribute to progression of the disease via several mechanisms including exacerbation of oxidative stress, initiation of inflammatory responses and triggering of Lewy body formation. In this minireview, we examine the putative role of iron in PD and its pharmacological chelation as a prospective therapeutic for the disease.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12882349     DOI： 10.1046/j.1474-9728.2002.00001.x

Source DB:  PubMed          Journal:  Aging Cell        ISSN： 1474-9718            Impact factor:   9.304


  15 in total

1.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

2.  Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.

Authors:  Sanjib Gogoi; Tamara Antonio; Subramanian Rajagopalan; Maarten Reith; Julie Andersen; Aloke K Dutta
Journal:  ChemMedChem       Date:  2011-05-12       Impact factor: 3.466

3.  Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.

Authors:  Balaram Ghosh; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

4.  Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease.

Authors:  Qi Xu; Monica Langley; Anumantha G Kanthasamy; Manju B Reddy
Journal:  J Nutr       Date:  2017-08-23       Impact factor: 4.798

5.  Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.

Authors:  Qingchun Zhang; Shufan Feng; Yulian Zhao; Bo Jin; Rufang Peng
Journal:  J Biol Inorg Chem       Date:  2021-05-08       Impact factor: 3.358

6.  Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.

Authors:  Ambreena Siddiq; Issam A Ayoub; Juan C Chavez; Leila Aminova; Sapan Shah; Joseph C LaManna; Stephanie M Patton; James R Connor; Robert A Cherny; Irene Volitakis; Ashley I Bush; Ingrid Langsetmo; Todd Seeley; Volkmar Gunzler; Rajiv R Ratan
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

Review 7.  Metal ion physiopathology in neurodegenerative disorders.

Authors:  Silvia Bolognin; Luigi Messori; Paolo Zatta
Journal:  Neuromolecular Med       Date:  2009-11-28       Impact factor: 3.843

8.  Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity.

Authors:  H L Liang; H T Whelan; J T Eells; M T T Wong-Riley
Journal:  Neuroscience       Date:  2008-03-26       Impact factor: 3.590

Review 9.  Intracellular iron transport and storage: from molecular mechanisms to health implications.

Authors:  Elizabeth L MacKenzie; Kenta Iwasaki; Yoshiaki Tsuji
Journal:  Antioxid Redox Signal       Date:  2008-06       Impact factor: 8.401

10.  Phytic Acid Protects against 6-Hydroxydopamine-Induced Dopaminergic Neuron Apoptosis in Normal and Iron Excess Conditions in a Cell Culture Model.

Authors:  Qi Xu; Anumantha G Kanthasamy; Manju B Reddy
Journal:  Parkinsons Dis       Date:  2011-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.